Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

The long-term prospects for the company are evolving with product approvals in China, build-up of consumer healthcare franchise, and a biosimilar pipeline.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes, according to a study published online Jan. 21 in JAMA Network ...

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

Semaglutide (known by its brandname Ozempic) has gained widespread attention for its weight loss benefits, but is officially ...

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.

“I’m making money to afford semagultide,” Rice, 42, who works three jobs to afford the expensive injectables, explained to her over 14,000 TikTok fans . Classified as a GLP-1, appetite-suppressing ...